RxDoctor Payments Data

Ethan Ben-Sorek, MD

Internal Medicine · New Hyde Park, NYNPI 1609878305

Payments from drug & device makers

$1,723in general payments, 2019–2025

Across 61 payments — averaging $28.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$488
  • AbbVie$368
  • Abbott$164
  • Amgen$147
  • Novartis$134
  • Alnylam Pharmaceuticals Inc.$123
  • plus $299 from 7 others

What the payments were for

  • Food & beverage$1,723100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,723 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$203,416
Medicare patients
382
Services billed
4,402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin24$39,360
JanuviaSitagliptin Phosphate25$28,940
EliquisApixaban20$28,220
OzempicSemaglutide11$21,721
XareltoRivaroxaban13$13,204
TradjentaLinagliptin16$12,872
Atorvastatin Calcium309$2,848
Rosuvastatin Calcium160$2,478
Amlodipine Besylate344$1,763
Metoprolol Succinate106$1,734
SynthroidLevothyroxine Sodium20$1,650
Albuterol Sulfate HfaAlbuterol Sulfate46$1,614
Levothyroxine Sodium122$1,453
Simvastatin129$1,340
Tamsulosin Hcl62$1,256

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$73$28,22020 claims
Novo NordiskOzempic$488$21,72111 claims
AbbVieSynthroid$368$1,65020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New Hyde Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →